Erika Mayer, MD, MPH, Dana-Farber Cancer Institute, discusses the exciting findings of the phase 3 lidERA study investigating ...

What sounds like a line from a dystopian thriller is, in fact, the reality for billions of people. Behind the sleek interfaces and free services lies a massive surveillance system that thrives on your ...

When shopping for new bedding, you'll undoubtedly run into both natural down and materials described as down alternatives. This prompts a lot of questions. Is down or down alternative better? What are ...

An international research team has identified a previously unknown mechanism by which the breast cancer drug tamoxifen can increase the risk of secondary tumors in the uterus. The study shows that ...

Throughout my career, various investment fads have risen and fallen, and while they all have their own distinct characteristics, they all share something in common: They're packaged as "alternative ...

Background: Breast cancer, a leading cause of cancer-related deaths, prompts research into chemoprevention strategies. This narrative review explores risk factors, assessment tools, and summarizes the ...

Tamoxifen (Nolvadex, Soltamox) is the most widely prescribed breast cancer therapy in the world. Some even call it the "backbone" of breast cancer treatment. Even with all that fanfare, tamoxifen has ...

One word defines the investing landscape in early 2025: uncertainty. From inflation and economic growth to geopolitics, the range of possible outcomes is broad. In uncertain times, diversification ...

Alternative investments aren’t so “alternative” anymore. Once the rarefied domain of institutional investors and some sophisticated individuals, alts—from hedge funds to private credit to ...

SAN ANTONIO — For patients with so-called “good-risk” ductal carcinoma in situ (DCIS) who did not have radiation therapy after breast-conserving surgery, adjuvant tamoxifen reduced their overall risks ...

Please provide your email address to receive an email when new articles are posted on . Patients with DCIS who received tamoxifen had a lower 15-year risk for ipsilateral breast cancer recurrence.